Tom Jukier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tom Jukier has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Gerken
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL
3 shared publications - Amanda Gross
Scott-Ritchey Research Center, Auburn University College of Veterinary Medicine, Auburn, AL, USA
2 shared publications - Andrew Chua
Department of Clinical Sciences College of Veterinary Medicine Auburn University Auburn Alabama USA
2 shared publications - Chu Zhang
Auburn University
2 shared publications - Kamoltip Thungrat
Departments of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
2 shared publications - Maureen Ann McMichael
Department of Clinical Sciences College of Veterinary Medicine Auburn University Auburn Alabama USA
2 shared publications
Latest Publications
- 20 April 2026
- Published by Wiley in Veterinary Record Case Reports
- Vol. 14 (2) , e70445
Brain herniation in a dobermann with polycythaemia vera
A 1.5‐year‐old, entire, female dobermann presented acutely comatose with seizures and tremors and was found to have marked erythrocytosis with a packed cell volume of 92%. The erythropoietin level was low, and the JAK2 gene mutation testing was negative. Despite multiple phlebotomies and a gradual decrease in packed cell volume, the dog deteriorated and developed respiratory arrest. Euthanasia was elected. Postmortem findings revealed a highly cellular bone marrow with approximately 70% haematopoietic cell lineages, aspiration pneumonia, as well as brain haemorrhage, necrosis and foramen magnum herniation, leading to respiratory arrest. The diagnostic findings were most consistent with polycythaemia vera, in which severe blood hyperviscosity likely caused cerebral hypoperfusion and vascular injury, explaining the neurological signs and postmortem changes. The neurological dysfunction likely contributed to aspiration pneumonia. Reported median survival time in dogs with polycythaemia vera is poor, emphasising the need for improved understanding of the disease to guide future management.
- 20 April 2026
- Published by Wiley in Veterinary Record Case Reports
- Vol. 14 (2) , e70445
Brain herniation in a dobermann with polycythaemia vera
A 1.5‐year‐old, entire, female dobermann presented acutely comatose with seizures and tremors and was found to have marked erythrocytosis with a packed cell volume of 92%. The erythropoietin level was low, and the JAK2 gene mutation testing was negative. Despite multiple phlebotomies and a gradual decrease in packed cell volume, the dog deteriorated and developed respiratory arrest. Euthanasia was elected. Postmortem findings revealed a highly cellular bone marrow with approximately 70% haematopoietic cell lineages, aspiration pneumonia, as well as brain haemorrhage, necrosis and foramen magnum herniation, leading to respiratory arrest. The diagnostic findings were most consistent with polycythaemia vera, in which severe blood hyperviscosity likely caused cerebral hypoperfusion and vascular injury, explaining the neurological signs and postmortem changes. The neurological dysfunction likely contributed to aspiration pneumonia. Reported median survival time in dogs with polycythaemia vera is poor, emphasising the need for improved understanding of the disease to guide future management.
- Open Access
- 1 April 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (4) , 1-6
Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration
Objective: To describe the pharmacokinetics of the IV formulation of levetiracetam administered intranasally and calculate the absolute bioavailability. Our hypothesis was that levetiracetam would show near complete absorption following a single intranasal dose. Methods: 8 healthy dogs (4 female, 4 male) from a canine colony were used in a crossover study comparing the pharmacokinetics of intranasal and IV levetiracetam. The study occurred from August through September 2024. A 100-mg dose of levetiracetam was administered via the intranasal and IV routes on separate occasions. Blood was collected from jugular catheters over a 24-hour period following dose administration. Plasma levetiracetam concentrations were analyzed using high-pressure liquid chromatography. Noncompartmental analysis was performed to describe the pharmacokinetics. Results: Median (minimum to maximum), maximal concentration, time to maximal concentration, and elimination half-life for the intranasal route were 7.85 µg/mL (range, 3.37 to 14.16), 0.98 hours (range, 0.22 to 1.00), and 2.83 hours (range, 2.44 to 3.76), respectively. Median (minimum to maximum) bioavailability was 61% (range, 34% to 85%). The maximal concentration achieved fell within the human reference interval for levetiracetam in 5 of 8 dogs. Conclusions: Levetiracetam was absorbed to a moderate degree following the intranasal route of administration and appeared to be well tolerated. Clinical Relevance: Levetiracetam is absorbed via the nasal administration route and could be considered a feasible route of administration for at-home rescue protocols. Although concentrations within the human reference interval were achieved in a majority of dogs, a clinical trial is necessary to determine if this method of administration would be effective in a clinical setting.
- 1 April 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (4) , 1-6
Open AccessPharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration
Objective: To describe the pharmacokinetics of the IV formulation of levetiracetam administered intranasally and calculate the absolute bioavailability. Our hypothesis was that levetiracetam would show near complete absorption following a single intranasal dose. Methods: 8 healthy dogs (4 female, 4 male) from a canine colony were used in a crossover study comparing the pharmacokinetics of intranasal and IV levetiracetam. The study occurred from August through September 2024. A 100-mg dose of levetiracetam was administered via the intranasal and IV routes on separate occasions. Blood was collected from jugular catheters over a 24-hour period following dose administration. Plasma levetiracetam concentrations were analyzed using high-pressure liquid chromatography. Noncompartmental analysis was performed to describe the pharmacokinetics. Results: Median (minimum to maximum), maximal concentration, time to maximal concentration, and elimination half-life for the intranasal route were 7.85 µg/mL (range, 3.37 to 14.16), 0.98 hours (range, 0.22 to 1.00), and 2.83 hours (range, 2.44 to 3.76), respectively. Median (minimum to maximum) bioavailability was 61% (range, 34% to 85%). The maximal concentration achieved fell within the human reference interval for levetiracetam in 5 of 8 dogs. Conclusions: Levetiracetam was absorbed to a moderate degree following the intranasal route of administration and appeared to be well tolerated. Clinical Relevance: Levetiracetam is absorbed via the nasal administration route and could be considered a feasible route of administration for at-home rescue protocols. Although concentrations within the human reference interval were achieved in a majority of dogs, a clinical trial is necessary to determine if this method of administration would be effective in a clinical setting.
- Open Access
- 21 January 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (1)
Efficacy of monotherapy with zonisamide and proposed reference interval in dogs with epilepsy: a cohort of 207 dogs (2011-2021)
Background: Zonisamide (ZNS) has become a popular antiseizure medication (ASM) to treat epilepsy in dogs. Dose adjustments based on plasma ZNS concentrations facilitate management, but efficacy evidence is limited. No reference interval (RI) is established in dogs. Hypothesis/Objectives: To assess ZNS efficacy and establish an RI for dogs with epilepsy. Animals: Two hundred seven dogs with non-structural epilepsy received ZNS monotherapy, with samples submitted for therapeutic drug monitoring (TDM). Methods: In this retrospective observational study, ZNS information was collected from the TDM data record library between November 2011 and May 2021. Exclusion criteria were structural epilepsy, receiving other ASMs, dogs’ age >6 years, or a duration of ZNS <3 months. Zonisamide response was assessed as described in the International Veterinary Epilepsy Task Force (IVETF) consensus. Plasma ZNS concentrations from responders (categories 1 [seizure freedom] and 2 [partial response]) were evaluated at the established RI. Results: Two hundred seven dogs could be assigned to IVETF response categories 1-3. The proportion of responders (59%, n = 123), including categories 1 (29%) and 2 (30%), was higher than non-responders (category 3, 41%, n = 84; P < .01). Based on the responders, an RI of 10-55 μg/mL is proposed. Conclusions and clinical importance: This study demonstrated that ZNS monotherapy is effective for treatment of non-structural epilepsy. The proposed RI, 10-55 μg/mL, is a broader range than that in human medicine, 10-40 μg/mL.
- 21 January 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (1)
Open AccessEfficacy of monotherapy with zonisamide and proposed reference interval in dogs with epilepsy: a cohort of 207 dogs (2011-2021)
Background: Zonisamide (ZNS) has become a popular antiseizure medication (ASM) to treat epilepsy in dogs. Dose adjustments based on plasma ZNS concentrations facilitate management, but efficacy evidence is limited. No reference interval (RI) is established in dogs. Hypothesis/Objectives: To assess ZNS efficacy and establish an RI for dogs with epilepsy. Animals: Two hundred seven dogs with non-structural epilepsy received ZNS monotherapy, with samples submitted for therapeutic drug monitoring (TDM). Methods: In this retrospective observational study, ZNS information was collected from the TDM data record library between November 2011 and May 2021. Exclusion criteria were structural epilepsy, receiving other ASMs, dogs’ age >6 years, or a duration of ZNS <3 months. Zonisamide response was assessed as described in the International Veterinary Epilepsy Task Force (IVETF) consensus. Plasma ZNS concentrations from responders (categories 1 [seizure freedom] and 2 [partial response]) were evaluated at the established RI. Results: Two hundred seven dogs could be assigned to IVETF response categories 1-3. The proportion of responders (59%, n = 123), including categories 1 (29%) and 2 (30%), was higher than non-responders (category 3, 41%, n = 84; P < .01). Based on the responders, an RI of 10-55 μg/mL is proposed. Conclusions and clinical importance: This study demonstrated that ZNS monotherapy is effective for treatment of non-structural epilepsy. The proposed RI, 10-55 μg/mL, is a broader range than that in human medicine, 10-40 μg/mL.
- Open Access
- 1 May 2025
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 86 (5) , 1-7
Premedication and general anesthetic agents decrease plasma concentration of the endocannabinoid anandamide in dogs
Objective: To determine the effect of premedication followed by isoflurane (ISO) versus sevoflurane (SEVO), length of general anesthesia (GA), and the amount of IV fluid administered on plasma endocannabinoid arachidonoyl ethanolamide (anandamide; AEA) concentrations in dogs undergoing GA. Methods: This study was an analysis of samples collected during a previously designed prospective, randomized, single-blinded experimental study involving 21 client-owned dogs undergoing GA. Samples were collected from March through October 2021. Dogs were randomized to ISO or SEVO as the inhalant anesthetic. Blood samples collected before and after GA were used to measure plasma AEA concentrations using HPLC-MS-MS. Data included signalment, length of GA (minutes), surgery performed, fluid volume administered (milliliters per kilogram), and treatment with NSAIDs or steroids. Statistical analyses included power analysis, normality testing, and adjusted linear mixed models. Results: Plasma AEA concentrations significantly decreased after GA in both groups. Least squares mean AEA concentration decreased from 29 to 12.3 ng/mL in the ISO group and from 26.6 to 11.1 ng/mL in the SEVO group. There were no significant differences between groups or associations with anesthesia duration, fluid volume, surgery, or NSAID/steroid use. Conclusions: Plasma AEA concentrations were significantly reduced after GA in both the ISO and SEVO groups. This reduction may be influenced by other anesthesia agents, such as dexmedetomidine, hydromorphone, and propofol. Clinical Relevance: This study is the first to highlight a potential interaction between premedication, GA, and endocannabinoid signaling. Further research is needed to explore these findings and their implications for pain management and neuroprotection.
- 1 May 2025
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 86 (5) , 1-7
Open AccessPremedication and general anesthetic agents decrease plasma concentration of the endocannabinoid anandamide in dogs
Objective: To determine the effect of premedication followed by isoflurane (ISO) versus sevoflurane (SEVO), length of general anesthesia (GA), and the amount of IV fluid administered on plasma endocannabinoid arachidonoyl ethanolamide (anandamide; AEA) concentrations in dogs undergoing GA. Methods: This study was an analysis of samples collected during a previously designed prospective, randomized, single-blinded experimental study involving 21 client-owned dogs undergoing GA. Samples were collected from March through October 2021. Dogs were randomized to ISO or SEVO as the inhalant anesthetic. Blood samples collected before and after GA were used to measure plasma AEA concentrations using HPLC-MS-MS. Data included signalment, length of GA (minutes), surgery performed, fluid volume administered (milliliters per kilogram), and treatment with NSAIDs or steroids. Statistical analyses included power analysis, normality testing, and adjusted linear mixed models. Results: Plasma AEA concentrations significantly decreased after GA in both groups. Least squares mean AEA concentration decreased from 29 to 12.3 ng/mL in the ISO group and from 26.6 to 11.1 ng/mL in the SEVO group. There were no significant differences between groups or associations with anesthesia duration, fluid volume, surgery, or NSAID/steroid use. Conclusions: Plasma AEA concentrations were significantly reduced after GA in both the ISO and SEVO groups. This reduction may be influenced by other anesthesia agents, such as dexmedetomidine, hydromorphone, and propofol. Clinical Relevance: This study is the first to highlight a potential interaction between premedication, GA, and endocannabinoid signaling. Further research is needed to explore these findings and their implications for pain management and neuroprotection.
- 17 July 2024
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 47 (6) , 461-468
Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats
The number of available antiseizure medications with demonstrated efficacy in cats is limited. As such, there is a need to evaluate the pharmacokinetics of newer medications so that proper dosing regimens can be made. Brivaracetam (BRV) is a more potent analogue of levetiracetam, and is Food and Drug Administration approved for use in people. The goal of this study was to describe the pharmacokinetics of intravenous and oral doses of BRV in healthy cats. A cross‐over study involving eight healthy cats, that were administered 10 mg of BRV intravenously as a bolus and orally in the fasted state. Blood samples were collected over 24 h. Analysis was performed using liquid chromatography‐mass spectrometry. Data were subjected to non‐compartmental analysis. Median (min–max) of maximal concentration, time to maximal concentration, area under the curve, elimination half‐life and oral absolute bioavailability were 902 (682–1036) ng/mL, 0.6 (0.5–2.0) h, 6.4 (5.2–7.2) h, 8145 (6669–9351) ng × h/mL and 100% (85–110) respectively. BRV appeared to be well tolerated by all cats. A single dose of BRV is well tolerated both orally and intravenously. Maximal concentrations are produced rapidly and within the human reference interval considered to be therapeutic.
- 17 July 2024
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 47 (6) , 461-468
Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats
The number of available antiseizure medications with demonstrated efficacy in cats is limited. As such, there is a need to evaluate the pharmacokinetics of newer medications so that proper dosing regimens can be made. Brivaracetam (BRV) is a more potent analogue of levetiracetam, and is Food and Drug Administration approved for use in people. The goal of this study was to describe the pharmacokinetics of intravenous and oral doses of BRV in healthy cats. A cross‐over study involving eight healthy cats, that were administered 10 mg of BRV intravenously as a bolus and orally in the fasted state. Blood samples were collected over 24 h. Analysis was performed using liquid chromatography‐mass spectrometry. Data were subjected to non‐compartmental analysis. Median (min–max) of maximal concentration, time to maximal concentration, area under the curve, elimination half‐life and oral absolute bioavailability were 902 (682–1036) ng/mL, 0.6 (0.5–2.0) h, 6.4 (5.2–7.2) h, 8145 (6669–9351) ng × h/mL and 100% (85–110) respectively. BRV appeared to be well tolerated by all cats. A single dose of BRV is well tolerated both orally and intravenously. Maximal concentrations are produced rapidly and within the human reference interval considered to be therapeutic.
- Open Access
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2165-2170
Urinary syndecan-1 in dogs anesthetized with isoflurane or sevoflurane: A randomized, prospective study
Background: Syndecan-1 (SDC1) is an established marker of endothelial glycocalyx shedding. Most research on SDC1 has focused on plasma or serum concentrations, and little is known about urine concentrations. Objectives: Measure urinary SDC1 concentrations in dogs undergoing anesthesia with either sevoflurane or isoflurane and assess the effects of anesthesia duration and IV crystalloids on urinary SDC1 concentrations. Animals: Thirty-one client-owned dogs undergoing anesthesia for magnetic resonance imaging (MRI) with or without surgery for suspected intervertebral disk disease (IVDD) were used. Methods: Dogs with suspected IVDD were randomized to undergo anesthesia with either sevoflurane or isoflurane. Urine was collected before and immediately after anesthesia for the analysis of SDC1. Urinary creatinine concentrations also were measured, and the ratio of urinary SDC1 to urinary creatinine (USCR) was used to account for dilution. Results: Median (range) USCR was significantly higher after anesthesia compared with baseline for all groups combined (P < .05). No significant difference was found between the groups for age, sex, weight, and type of anesthesia. Multiple regression analysis of the effect of the independent variables inhalant type, age, weight, sex, anesthesia time, surgery, and quantity of IV fluids on the dependent variable SDC1 found that only the quantity of IV fluids significantly predicted a change (P < .001). Conclusions and Clinical Importance: The total volume of lactated Ringer's solution administered to anesthetized dogs may affect USCR. Further investigations are warranted to evaluate the relationship between IV fluids and SDC1.
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2165-2170
Open AccessUrinary syndecan-1 in dogs anesthetized with isoflurane or sevoflurane: A randomized, prospective study
Background: Syndecan-1 (SDC1) is an established marker of endothelial glycocalyx shedding. Most research on SDC1 has focused on plasma or serum concentrations, and little is known about urine concentrations. Objectives: Measure urinary SDC1 concentrations in dogs undergoing anesthesia with either sevoflurane or isoflurane and assess the effects of anesthesia duration and IV crystalloids on urinary SDC1 concentrations. Animals: Thirty-one client-owned dogs undergoing anesthesia for magnetic resonance imaging (MRI) with or without surgery for suspected intervertebral disk disease (IVDD) were used. Methods: Dogs with suspected IVDD were randomized to undergo anesthesia with either sevoflurane or isoflurane. Urine was collected before and immediately after anesthesia for the analysis of SDC1. Urinary creatinine concentrations also were measured, and the ratio of urinary SDC1 to urinary creatinine (USCR) was used to account for dilution. Results: Median (range) USCR was significantly higher after anesthesia compared with baseline for all groups combined (P < .05). No significant difference was found between the groups for age, sex, weight, and type of anesthesia. Multiple regression analysis of the effect of the independent variables inhalant type, age, weight, sex, anesthesia time, surgery, and quantity of IV fluids on the dependent variable SDC1 found that only the quantity of IV fluids significantly predicted a change (P < .001). Conclusions and Clinical Importance: The total volume of lactated Ringer's solution administered to anesthetized dogs may affect USCR. Further investigations are warranted to evaluate the relationship between IV fluids and SDC1.
- Open Access
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10, 1307888
Pharmacokinetics and tolerability of a veterinary phenobarbital product in healthy dogs
Introduction: Phenobarbital has been used for many decades in both human and veterinary epileptic patients. Many formulations for a particular drug exist, most of which are marketed for humans. Recently a veterinary specific phenobarbital product has been introduced to the market in the United States. Utilizing a specific formulation to treat patients may help decrease the issue of bioequivalence between one pharmaceutical product to another. Therefore, the goal of this study was to determine single and multiple dosing pharmacokinetics and tolerability of a veterinary specific phenobarbital product over a 4-week time period.Materials and methods: 8 Healthy dogs from a canine research colony were used in the study.Results: Overall, this phenobarbital formulation was well tolerated in the dogs in this study. Cmax, Tmax, half-life, and AUC after single 12 mg/kg oral dose were 23.5 μg/mL, 4.2 h, 94 h, and 2,758 h*μg/mL. Following chronic dosing, these parameters were 29.1 μg/mL, 3.4 h, 70 h, and 2,971 h*μg/mL, respectively.Discussion: This formulation demonstrated a mean absolute bioavailability of 100%, with similar pharmacokinetic properties to previously published data.
- 5 January 2024
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10, 1307888
Open AccessPharmacokinetics and tolerability of a veterinary phenobarbital product in healthy dogs
Introduction: Phenobarbital has been used for many decades in both human and veterinary epileptic patients. Many formulations for a particular drug exist, most of which are marketed for humans. Recently a veterinary specific phenobarbital product has been introduced to the market in the United States. Utilizing a specific formulation to treat patients may help decrease the issue of bioequivalence between one pharmaceutical product to another. Therefore, the goal of this study was to determine single and multiple dosing pharmacokinetics and tolerability of a veterinary specific phenobarbital product over a 4-week time period.Materials and methods: 8 Healthy dogs from a canine research colony were used in the study.Results: Overall, this phenobarbital formulation was well tolerated in the dogs in this study. Cmax, Tmax, half-life, and AUC after single 12 mg/kg oral dose were 23.5 μg/mL, 4.2 h, 94 h, and 2,758 h*μg/mL. Following chronic dosing, these parameters were 29.1 μg/mL, 3.4 h, 70 h, and 2,971 h*μg/mL, respectively.Discussion: This formulation demonstrated a mean absolute bioavailability of 100%, with similar pharmacokinetic properties to previously published data.
- 1 August 2023
- Vol. 64 (8) , 727-732
Clinical description with magnetic resonance appearance of a high-grade undefined optic nerve glioma with intracranial extension
A 4-year-old mixed-breed dog was presented for hyphema and glaucoma of the right eye. Enucleation of the right globe was carried out, and histopathology examination revealed an optic nerve glioma with incomplete surgical margins. At 8 wk after surgery, the dog had depressed mentation and a diminished pupillary light reflex of the left eye. Magnetic resonance imaging revealed an irregular, heterogeneously T2 hyperintense/T1 isointense mass in the region of the optic chiasm. Compression of the rostral thalamus was present, with effacement of the pituitary gland and involvement of the right orbit. The dog was euthanized 4.5 mo after initial presentation. An undefined glioma of the right optic nerve with extension to the diencephalon was diagnosed on necropsy.
- 1 August 2023
- Vol. 64 (8) , 727-732
Clinical description with magnetic resonance appearance of a high-grade undefined optic nerve glioma with intracranial extension
A 4-year-old mixed-breed dog was presented for hyphema and glaucoma of the right eye. Enucleation of the right globe was carried out, and histopathology examination revealed an optic nerve glioma with incomplete surgical margins. At 8 wk after surgery, the dog had depressed mentation and a diminished pupillary light reflex of the left eye. Magnetic resonance imaging revealed an irregular, heterogeneously T2 hyperintense/T1 isointense mass in the region of the optic chiasm. Compression of the rostral thalamus was present, with effacement of the pituitary gland and involvement of the right orbit. The dog was euthanized 4.5 mo after initial presentation. An undefined glioma of the right optic nerve with extension to the diencephalon was diagnosed on necropsy.
- Open Access
- 28 April 2023
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10
Case report: Recovery and sequential imaging of a patient with osmotic demyelination syndrome
A 4-year-old neutered-male Australian Shepherd was presented to an emergency and referral hospital for an acute onset of neurologic signs and abnormal mentation. Seven days prior, the patient had been diagnosed with hypoadrenocorticism and was treated accordingly at another hospital. Based on recent clinical history, the neurologic signs were consistent with thalamic and brainstem deficits and suspected to be caused by osmotic demyelination syndrome secondary to rapid correction of hyponatremia. A brain MRI confirmed lesions consistent with osmotic demyelination syndrome. The patient's clinical signs initially worsened, and he required intensive nursing care with multimodal sedation, close monitoring of electrolytes and tailored fluid therapy. The patient recovered and was discharged on day seven of hospitalization. Four and a half months later, re-evaluation of the patient showed complete resolution of the neurological deficits with a now unremarkable neurological exam, and follow-up MRI revealed still present, yet improved bilateral thalamic lesions. This is the first known veterinary case report of sequential brain imaging of a dog that has recovered from osmotic demyelination syndrome. In humans, patients can have evidence of near to full clinical recovery, yet imaging findings may still be abnormal several months after recovery. This report details similar imaging findings in a canine with improved clinical signs, despite persistent lesions on brain MRI. Prognosis of canines with osmotic demyelination syndrome may be better than previously perceived, despite the severity of clinical signs and brain lesions apparent on MRI.
- 28 April 2023
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10
Open AccessCase report: Recovery and sequential imaging of a patient with osmotic demyelination syndrome
A 4-year-old neutered-male Australian Shepherd was presented to an emergency and referral hospital for an acute onset of neurologic signs and abnormal mentation. Seven days prior, the patient had been diagnosed with hypoadrenocorticism and was treated accordingly at another hospital. Based on recent clinical history, the neurologic signs were consistent with thalamic and brainstem deficits and suspected to be caused by osmotic demyelination syndrome secondary to rapid correction of hyponatremia. A brain MRI confirmed lesions consistent with osmotic demyelination syndrome. The patient's clinical signs initially worsened, and he required intensive nursing care with multimodal sedation, close monitoring of electrolytes and tailored fluid therapy. The patient recovered and was discharged on day seven of hospitalization. Four and a half months later, re-evaluation of the patient showed complete resolution of the neurological deficits with a now unremarkable neurological exam, and follow-up MRI revealed still present, yet improved bilateral thalamic lesions. This is the first known veterinary case report of sequential brain imaging of a dog that has recovered from osmotic demyelination syndrome. In humans, patients can have evidence of near to full clinical recovery, yet imaging findings may still be abnormal several months after recovery. This report details similar imaging findings in a canine with improved clinical signs, despite persistent lesions on brain MRI. Prognosis of canines with osmotic demyelination syndrome may be better than previously perceived, despite the severity of clinical signs and brain lesions apparent on MRI.